JPH10507776A - トロンボポエチン受容体に結合するペプチドおよび化合物 - Google Patents
トロンボポエチン受容体に結合するペプチドおよび化合物Info
- Publication number
- JPH10507776A JPH10507776A JP9501903A JP50190397A JPH10507776A JP H10507776 A JPH10507776 A JP H10507776A JP 9501903 A JP9501903 A JP 9501903A JP 50190397 A JP50190397 A JP 50190397A JP H10507776 A JPH10507776 A JP H10507776A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- peptide
- group
- bond
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.トロンボポエチン受容体に結合する化合物であって、該化合物が: (1)約8000ダルトン未満の分子量であり、 (2)IC50で表したときの、トロンボポエチン受容体に対する結合親和性 が約100μmにすぎない ような化合物。 2.請求項1の化合物であって、該化合物がペプチドであり、且つ 該ペプチドの0〜全ての-C(O)NH-結合が、 -CH2-OC(O)NR-結合;ホスホネート結合;-CH2-S(O)2NR-結 合;-CH2NR-結合:および-C(O)NR6-結合;および-NHC(O)NH-結合 (ここでRは水素または低級アルキルであり、R6は低級アルキルである) からなる群から選択される結合によって置換されており、 さらに、前記ペプチドまたはペプチド擬態物のN末端が、 -NRR1基;-NRC(O)R基;NRC(O)OR基;-NRS(O)2R基;- NHC(O)NHR基:スクシンイミド基;ベンジルオキシカルボニル-NH-基; およびフェニル環上に、低級アルキル、低級アルコキシ、塩素、および臭素から なる群から選択される、1〜3個の置換基を有するベンジルオキシカルボニル- NH-基(ここで、RおよびR1は水素および低級アルキルからなる群から独立に 選択される) からなる群から選択され、 さらに、前記ペプチドまたはペプチド擬態物のC末端が、式-C(O)R2( ここでR2はヒドロキシ、低級アルコキシおよび-NR3R4(ここで、R3および R4水素および低級アルキルからなる群から独立に選択され、且つ、-NR3R4の 窒素原子は、環状ペプチドを形成させるために、任意にペプチドのN末端のアミ ン基であり得る)からなる群から選択される)を有するような化合物および生理 学的に受容可能なそれらの塩。 3.薬学的に受容できる担体とともに、請求項1の化合物を具備する薬学的組成 物。 4.トロンボポエチンアゴニストによる治療に対して感受性を有する疾病を患つ ている患者の治療方法であって、患者に、請求項1の化合物を治療的有効用量ま たは有効量投与することを含んでなる方法。 5.請求項4の方法であって、患者に投与される化合物がペプチドであり、 該ペプチドの0〜全ての-C(O)NH-結合が、 -CH2OC(O)NR-結合;ホスホネート結合;-CH2-S(O)2NR-結 合;-CH2NR-結合:-C(O)NR6-結合:および-NHC(O)NH-結合(ここ でRは水素または低級アルキルであり、R6は低級アルキルである) からなる群から選択される結合によって置換され、 さらに、前記ペプチドまたはペプチド擬態物のN末端が、 -NRR1基:-NRC(O)R基;NRC(O)OR基;-NRS(O)2R基;- NHC(O)NHR基;スクシンイミド基;ベンジルオキシカルボニル-NH-基; およびフェニル環上に、低級アルキル、低級アルコキシ、塩素、および臭素から なる群から選択される、1〜3個の置換基を有するベンジルオキシカルボニル- NH-基(ここで、RおよびR1は水素および低級アルキルからなる群から独立に 選択される) からなる群から選択され、 さらに、前記ペプチドまたはペプチド擬態物のC末端が、式-C(O)R2( ここでR2はヒドロキシ、低級アルコキシおよび-NR3R4(ここで、R3および R4は、水素および低級アルキルからなる群から独立に選択され、環状ペプチド を形成させるために、-NR3R4基の窒素原子は、任意に、ペプチドのN末端の アミン基であり得る)からなる群から選択される)を有する ような化合物および生理学的に受容可能なそれらの塩である方法。 6.請求項2の化合物であって、前記化合物がアミノ酸配列: X1X2X3X4X5X6X7 (ここで、X1はC,L,M,P,Q,V;X2はF,K,L,N,Q,R,S,Tまたは V;X3はC,F,I,L,M,R,S,VまたはW:X4は遺伝的にコードされる20の L-アミノ酸のうちの何れか;X5はA,D,E,G,K,M,Q,R,S,T,VまたはY ;X6はC,F,G,L,M,S,V,WまたはY;およびX7はC,G,I,K,L,M,N, RまたはVである) を具備する化合物。 7.請求項6の化合物であって、前記アミノ酸配列が環状である化合物。 8.請求項6の化合物であって、前記アミノ酸配列が2量体化されている化合物 。 9.請求項6の化合物であって、該化合物がアミノ酸配列: CX2X3X4X5X6X7 (ここで、X2はK,L,N,Q,R,S,TまたはV;X3はC,F,I,L,M,R, SまたはV;X4は遺伝的にコードされる20のL-アミノ酸のうちの何れか;X5 はA,D,E,G,S,VまたはY;X6はC,F,G,L,M,S,V,WまたはY;およ びX7はC,G,I,K,L,M,N,RまたはVである) を具備する化合物。 10.請求項8の化合物であって、X4がA,E,G,H,K,L,M,P,Q,R,S,T またはWである化合物。 11.請求項10の化合物であって、X2がSまたはT;X3がLまたはR;X6 がR;X5がD,EまたはG;X6がF,LまたはW;X7がI,K,L,RまたはVで ある化合物。 12.請求項9の化合物であって、前記化合物がアミノ酸配列: X8CX2X3X4X5X6X7 (ここで;X2はF,K,L,N,Q,R,S,TまたはV;X3はC,F,J,L, M,R,S,VまたはW;X4は遺伝的にコードされる20のL-アミノ酸の何れか; X5はA,D,E,G,K,M,Q,R,S.T,VまたはY;X6はC,F,G,L,M,S,V ,WまたはY;X7はC,G,I,K,L,M,N,RまたはV;およびX8は遺伝的にコ ードされる20のL-アミノ酸のうちの何れかである) を具備する化合物 13.請求項12の化合物であって、X8がG,S,YまたはRである化合物。 14.請求項12の化合物であって、前記化合物が、アミノ酸配列:GGCTL REWLHGGFCGGを具備する化合物。 15.請求項6の化合物であって、前記化合物がアミノ酸配列: X8GX1X2X3X4X5WX7 (ここでX1はL,M,P,QまたはV;X2はF,R,SまたはT;X3はF, L,VまたはW;X4はA,K,L,M,R,S,VまたはT;X5はA,E,G,K,M,Q ,R,SまたはT; X7はC,I.K.L,MまたはV;およびX8は、遺伝的にコードされる20のL-ア ミノ酸のうちの何れかである) を具備する化合物。 16.請求項15の化合物であって、X1がP;X2がT;X3がL;X4がR;X5 がEまたはQ;X7がIまたはLである化合物。 17.請求項16の化合物であって、前記化合物がアミノ酸配列: X9X8GX1X2X3X4X5WX7 (ここで、X8はA,C,D,E,K,L,Q,R,S,TまたはV;およびX9は A,C,E,G,I.L,M,P,R,Q,S,TまたはVである) を具備する化合物。 18.請求項17の化合物であって、X8がD,EまたはK;およびX9がAまた はIである化合物 19.請求項18の化合物であって、前記化合物が、GGCADGPTLREW ISFCGG;GNADGPTLRQWLEGRRPKN;GGCADGPTLR EWISFCGGK;TIKGPTLRQWLKSREHTS;SIEGPTLR EWLTSRTPHS;LAIEGPTLRQWLHGNGRDT;CADGPT LREWISFC;およびIEGPTLRQWLAARAからなる群から選択さ れる化合物。 20.請求項4の方法であって、患者に投与される前記化合物がアミノ酸配列: CX2X3X4X5X6X7 (ここで、X2はK,L,N,Q,R,S,TまたはV;X3はC,F,I,L,M, R,SまたはV;X4は遺伝的にコードされる20のL-アミノ酸のうちの何れか; X5はA,D,E,G,S,VまたはY;X6はC,F,G,L,M,S,V,WまたはY;お よびX7はC,G,I,K,L,M,N,RまたはVである) を具備する方法。 21.請求項20の方法であって、X4がA,E,G,H,K,L,M,P,Q,R,S,T またはWである方法。 22.請求項21の方法であって、X2がSまたはT;X3がLまたはR;X4が R:X5がD,EまたはG:X6がF,LまたはW:X7がI,K,L,RまたはVで ある方法。 23.請求項22の方法であって、患者に投与される前記化合物がアミノ酸配列 :GGCTLREWLHGGFCGGを具備する方法。 24.請求項4の方法であって、トロンボポエチンアゴニストに感受性を有する 疾患が: 化学療法、放射線療法、または骨髄移植によって生じる血液学的疾患 および血小板減少症 からなる群から選択される方法。 25.請求項4の方法であって、患者に投与される前記化合物がアミノ酸配列: X8GX1X2X3X4X5WX7 (ここで、X1はL,M,P,QまたはV;X2はF,R,SまたはT;X3はF ,L,VまたはW;X4はA,K,L,M,R,S,VまたはT;X5はA,E,G,K,M, Q,R,SまたはT:X7はC,I,K,L,MまたはV;およびX8残基は、遺伝的に コードされる20のL-アミノ酸のうちの何れかである) を具備する方法。 26.請求項25の方法であって、X1がP;X2がT;X3がL;X4がR;X5 がEまたはQ;X7がIまたはLである方法。 27.請求項26の方法であって、前記化合物がアミノ酸配列: X9X8GX1X2X3X4X5WX7 (ここで、X8はA,C,D,E,K,L,Q,R,S,TまたはVであり;X9はA, C,E,G,I,L,M,P,Q,R,S,TまたはV;および) を具備する方法。 28.請求項27の方法で、X8がD,EまたはKであり;X9がAまたはIであ る方法。 29.請求項28の方法で、患者に投与される化合物が、GGCADGPTLR EWISFCGG;GNADGPTLRQWLEGRRPKN;GGCADGPT LREWISFCGGK;TIKGPTLRQWLKSREHTS;SIEGPT LREWLTSRTPHS;LAIEGPTLRQWLHGNGRDT;CADG PTLREWISFC;およびIEGPTLRQWLAARAから なる群から選択される方法。 30.トロンボポエチン受容体に結合する化合物であって、前記化合物が からなる群から選択される化合物。 31.トロンボポエチンアゴニストによる治療に対して感受性を有する疾病を患 っている患者の治療方法であって、患者に、 からなる群から選択される化合物を投与することを具備する方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US485,301 | 1990-02-26 | ||
US48530195A | 1995-06-07 | 1995-06-07 | |
US47812895A | 1995-06-07 | 1995-06-07 | |
US08/478,128 | 1995-06-07 | ||
US08/485,301 | 1995-06-07 | ||
US478,128 | 1995-06-07 | ||
PCT/US1996/009623 WO1996040750A1 (en) | 1995-06-07 | 1996-06-07 | Peptides and compounds that bind to a thrombopoietin receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10507776A true JPH10507776A (ja) | 1998-07-28 |
JP3059218B2 JP3059218B2 (ja) | 2000-07-04 |
Family
ID=27045796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9501903A Expired - Lifetime JP3059218B2 (ja) | 1995-06-07 | 1996-06-07 | トロンボポエチン受容体に結合するペプチドおよび化合物 |
Country Status (27)
Country | Link |
---|---|
US (2) | US6083913A (ja) |
EP (4) | EP2338897A1 (ja) |
JP (1) | JP3059218B2 (ja) |
KR (1) | KR100436680B1 (ja) |
CN (2) | CN1966520B (ja) |
AR (1) | AR003431A1 (ja) |
AT (1) | ATE390439T1 (ja) |
BR (1) | BR9608587A (ja) |
CA (2) | CA2636432C (ja) |
CZ (1) | CZ291749B6 (ja) |
DE (1) | DE69637473T2 (ja) |
DK (1) | DK0885242T3 (ja) |
EA (1) | EA001220B1 (ja) |
ES (1) | ES2303338T3 (ja) |
HK (1) | HK1015380A1 (ja) |
HU (1) | HU227678B1 (ja) |
IL (1) | IL122102A (ja) |
MX (1) | MX9709315A (ja) |
NO (2) | NO317737B1 (ja) |
NZ (1) | NZ310778A (ja) |
PE (1) | PE7898A1 (ja) |
PL (1) | PL188795B1 (ja) |
PT (1) | PT885242E (ja) |
TR (1) | TR199701526T1 (ja) |
TW (1) | TW518341B (ja) |
WO (1) | WO1996040750A1 (ja) |
ZA (1) | ZA964814B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007504132A (ja) * | 2003-08-28 | 2007-03-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 受容体に結合するペプチドおよび化合物 |
JP2008532505A (ja) * | 2005-03-10 | 2008-08-21 | ナスカセル テクノロジーズ アーゲー. | 二量体または多量体のマイクロタンパク質 |
JP2011057690A (ja) * | 2002-09-18 | 2011-03-24 | Ortho-Mcneil Pharmaceutical Inc | 血小板および造血幹細胞の産生の増大方法 |
JP2017536330A (ja) * | 2014-09-11 | 2017-12-07 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤 |
JP2020528903A (ja) * | 2017-07-26 | 2020-10-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 標的放射線治療誘発性血管完全性を保護する方法 |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
EP2338897A1 (en) * | 1995-06-07 | 2011-06-29 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
US6172210B1 (en) * | 1996-04-02 | 2001-01-09 | Blood Center Research Foundation | DNA encoding phospholipid scramblase |
US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
US6930084B1 (en) | 1996-11-06 | 2005-08-16 | The Regents Of The University Of California | Treating arthritis with TNF receptor releasing enzyme |
US6593456B1 (en) | 1996-11-06 | 2003-07-15 | The Regents Of The University Of California | Tumor necrosis factor receptor releasing enzyme |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
CA2328252A1 (en) * | 1998-04-14 | 1999-10-21 | Katherine Louisa Widdowson | Receptor ligands |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
TWI250988B (en) * | 1998-10-23 | 2006-03-11 | Kirin Amgen Inc | Thrombopoietic compounds |
ATE284415T1 (de) | 1999-01-06 | 2004-12-15 | Genentech Inc | Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) |
US6911314B2 (en) | 1999-05-14 | 2005-06-28 | The Regents Of The University Of California | Screening for drugs that affect TNF receptor releasing enzyme |
JP2003509478A (ja) | 1999-09-21 | 2003-03-11 | エモリー・ユニバーシティ | 血小板関連障害を処置する方法および組成物 |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
DK1282437T3 (da) | 2000-05-16 | 2008-06-30 | Genentech Inc | Behandling af brusklidelser |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
JP3966816B2 (ja) | 2000-05-30 | 2007-08-29 | 中外製薬株式会社 | トロンボポエチン様活性を有する化合物 |
ATE320450T1 (de) | 2000-12-05 | 2006-04-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US7169931B2 (en) | 2001-01-26 | 2007-01-30 | Shionogi & Co., Ltd. | Cyclic compounds exhibiting thrombopoietin receptor agonism |
AU2002307062A1 (en) * | 2001-04-02 | 2002-10-15 | Purdue Pharma L.P. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
AU2002363522A1 (en) * | 2001-11-06 | 2003-05-19 | Ho Chris Meichung Wang | System and method for improved computer drug design |
CN1319967C (zh) * | 2002-01-18 | 2007-06-06 | 安斯泰来制药有限公司 | 2-酰基氨基噻唑衍生物或其盐 |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
AR040083A1 (es) | 2002-05-22 | 2005-03-16 | Smithkline Beecham Corp | Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
CA2495184A1 (en) | 2002-08-14 | 2004-02-26 | Nissan Chemical Industries, Ltd. | Thrombopoietin receptor activators and process for their production |
FI20021762A0 (fi) * | 2002-10-03 | 2002-10-03 | Karyon Oy Ab Ltd | Uusia terapeuttisia aineita ja valmisteita |
TWI324593B (en) | 2002-10-09 | 2010-05-11 | Nissan Chemical Ind Ltd | Pyrazolone compounds and thrombopoietin receptor activator |
US7736909B2 (en) * | 2003-01-09 | 2010-06-15 | Board Of Regents, The University Of Texas System | Methods and compositions comprising capture agents |
NZ563042A (en) * | 2003-05-12 | 2008-09-26 | Affymax Inc | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds |
MXPA05012313A (es) * | 2003-05-12 | 2006-04-18 | Affymax Inc | Peptidos que se unen al receptor de eritropoyetina. |
DE602004028725D1 (de) * | 2003-05-12 | 2010-09-30 | Affymax Inc | Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen |
KR101163683B1 (ko) | 2003-05-12 | 2012-07-10 | 아피맥스, 인크. | 에리스로포이에틴 수용체에 결합하는 신규의 펩티드 |
WO2004108078A2 (en) * | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Rationally designed antibodies |
US7601746B2 (en) | 2003-08-12 | 2009-10-13 | Shionogi & Co., Ltd. | Compounds exhibiting thrombopoietin receptor agonism |
US7723295B2 (en) * | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
TW200526638A (en) | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
US20060210542A1 (en) * | 2004-08-16 | 2006-09-21 | Yurkow Edward J | Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
CN100432102C (zh) * | 2004-09-30 | 2008-11-12 | 百瑞全球有限公司 | 血小板增进蛋白及其应用 |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
EP1814910A4 (en) * | 2004-11-11 | 2009-04-29 | Affymax Inc | NEW AT ERYTHROPOIETIN RECEPTOR BINDING PEPTIDES |
EP1819692A1 (en) | 2004-12-08 | 2007-08-22 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
CA2590204C (en) | 2004-12-14 | 2012-12-04 | Nissan Chemical Industries, Ltd. | Amide compounds and thrombopoietin receptor activators |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
EA200800109A1 (ru) * | 2005-06-23 | 2008-06-30 | Аплаген Гмбх | Суправалентные соединения |
JP5071375B2 (ja) | 2005-07-15 | 2012-11-14 | 日産化学工業株式会社 | チオフェン化合物及びトロンボポエチンレセプター活性化剤 |
TWI330184B (en) | 2005-07-20 | 2010-09-11 | Nissan Chemical Ind Ltd | Pyrazole compounds and thrombopoietin receptor activators |
JP5205967B2 (ja) | 2005-11-07 | 2013-06-05 | 日産化学工業株式会社 | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
AU2006313491B2 (en) * | 2005-11-08 | 2011-01-06 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
US7879318B2 (en) * | 2006-01-23 | 2011-02-01 | Mcw Research Foundation, Inc. | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand |
WO2007142308A1 (ja) | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
EP2452674B1 (en) * | 2006-08-08 | 2014-03-26 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
WO2008095004A2 (en) * | 2007-01-31 | 2008-08-07 | Affymax, Inc. | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
US20090054332A1 (en) * | 2007-06-21 | 2009-02-26 | Conjuchem Biotechnologies, Inc. | Thombopoietin peptide conjugates |
CA2694567C (en) | 2007-07-31 | 2013-04-23 | Shionogi & Co., Ltd. | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof |
WO2009029682A1 (en) * | 2007-08-28 | 2009-03-05 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
US8278057B2 (en) * | 2007-09-14 | 2012-10-02 | Nestec S.A. | Addressable antibody arrays and methods of use |
US8637455B2 (en) * | 2007-10-22 | 2014-01-28 | Affinergy, Llc | Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces |
CN101481352A (zh) | 2008-01-10 | 2009-07-15 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
US9493551B2 (en) | 2009-02-24 | 2016-11-15 | Alexion Pharmaceuticals, Inc. | Antibodies containing therapeutic TPO/EPO mimetic peptides |
DK3127427T3 (da) | 2009-05-29 | 2020-04-06 | Novartis Ag | Fremgangsmåder til administration af trombopoietinagonistforbindelser |
AU2010253797B2 (en) * | 2009-05-29 | 2015-03-12 | Opko Health, Inc. | Peptoid ligands for isolation and treatment of autoimmune T-cells |
WO2010141421A1 (en) * | 2009-06-02 | 2010-12-09 | The Board Of Regents Of The University Of Texas System | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases |
TW201124726A (en) * | 2009-10-16 | 2011-07-16 | Univ Texas | Compositions and methods for producing coded peptoid libraries |
JP5704073B2 (ja) | 2009-10-23 | 2015-04-22 | 日産化学工業株式会社 | 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2011098095A1 (en) | 2010-02-09 | 2011-08-18 | Aplagen Gmbh | Peptides binding the tpo receptor |
CN104045715B (zh) * | 2013-03-15 | 2018-05-01 | 兰州大学 | 二聚体化融合蛋白的制备及应用 |
AU2020396647A1 (en) | 2019-12-06 | 2022-07-07 | Ajinomoto Co., Inc. | Method for producing peptide having physiological activity, and peptide comprising short linker |
TW202300178A (zh) | 2021-03-18 | 2023-01-01 | 美商西根公司 | 內化的生物活性化合物偶聯物選擇性釋放藥物 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3645090A (en) | 1969-06-19 | 1972-02-29 | Citizen Watch Co Ltd | Day-date quick-adjuster for calender timepiece |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4612132A (en) | 1984-07-20 | 1986-09-16 | Chevron Research Company | Modified succinimides |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
DK167813B1 (da) * | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
US5571508A (en) | 1989-12-18 | 1996-11-05 | Amrad Corporation Limited | Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor |
US5141851A (en) * | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
EP0604552B1 (en) | 1991-09-18 | 1997-02-12 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5359115A (en) | 1992-03-26 | 1994-10-25 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
DE69332222T3 (de) | 1992-06-11 | 2007-05-10 | Alkermes Controlled Therapeutics, Inc., Cambridge | Enythropoietin enthaltendes arzneimittelabgabesystem |
US5420328A (en) | 1992-09-11 | 1995-05-30 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
EP0673387B1 (en) * | 1992-12-11 | 1999-09-22 | University Of Florida | Materials and methods for control of pests |
US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
CA2170357A1 (en) | 1993-08-25 | 1995-03-02 | David Digiusto | Method for producing a highly enriched population of hematopoietic stem cells |
WO1995011992A1 (en) | 1993-10-27 | 1995-05-04 | The Regents Of The University Of California | Antiviral compounds |
WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
GB2285446B (en) | 1994-01-03 | 1999-07-28 | Genentech Inc | Thrombopoietin |
CN1148408A (zh) | 1994-02-14 | 1997-04-23 | 津莫吉尼蒂克斯公司 | 血细胞生成蛋白及其制造材料和方法 |
AU1843595A (en) | 1994-02-14 | 1995-08-29 | University Of Washington | Methods for stimulating erythropoiesis using thrombopoietin |
SG79882A1 (en) | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
BR9506017A (pt) | 1994-03-31 | 1997-10-14 | Amagen Inc | Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um polipeptideo Mgdf e poipeptideo glicol solúvel em água a um polipeptideo mgdf |
US5571686A (en) | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
AU4163196A (en) * | 1994-11-30 | 1996-06-19 | Zymogenetics Inc. | Low molecular weight thrombopoietin |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
EP2338897A1 (en) * | 1995-06-07 | 2011-06-29 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US8157793B2 (en) | 2006-10-25 | 2012-04-17 | Terumo Kabushiki Kaisha | Manipulator for medical use |
JP2023049441A (ja) | 2021-09-29 | 2023-04-10 | トヨタ紡織株式会社 | 乗物用シート |
-
1996
- 1996-06-07 EP EP10184658A patent/EP2338897A1/en not_active Withdrawn
- 1996-06-07 US US08/973,225 patent/US6083913A/en not_active Expired - Lifetime
- 1996-06-07 HU HU9900921A patent/HU227678B1/hu unknown
- 1996-06-07 ZA ZA9604814A patent/ZA964814B/xx unknown
- 1996-06-07 EP EP07024601A patent/EP1961760A3/en not_active Withdrawn
- 1996-06-07 PE PE1996000437A patent/PE7898A1/es not_active IP Right Cessation
- 1996-06-07 CN CN200610154077XA patent/CN1966520B/zh not_active Expired - Lifetime
- 1996-06-07 KR KR1019970709057A patent/KR100436680B1/ko not_active IP Right Cessation
- 1996-06-07 EA EA199700359A patent/EA001220B1/ru not_active IP Right Cessation
- 1996-06-07 CA CA2636432A patent/CA2636432C/en not_active Expired - Lifetime
- 1996-06-07 DE DE69637473T patent/DE69637473T2/de not_active Expired - Lifetime
- 1996-06-07 CN CNB961961422A patent/CN1315870C/zh not_active Expired - Lifetime
- 1996-06-07 CA CA002223449A patent/CA2223449C/en not_active Expired - Lifetime
- 1996-06-07 BR BR9608587A patent/BR9608587A/pt active Search and Examination
- 1996-06-07 PL PL96323917A patent/PL188795B1/pl unknown
- 1996-06-07 EP EP08075859A patent/EP2055712A1/en not_active Withdrawn
- 1996-06-07 TR TR97/01526T patent/TR199701526T1/xx unknown
- 1996-06-07 NZ NZ310778A patent/NZ310778A/xx not_active IP Right Cessation
- 1996-06-07 CZ CZ19973897A patent/CZ291749B6/cs not_active IP Right Cessation
- 1996-06-07 AT AT96919241T patent/ATE390439T1/de active
- 1996-06-07 WO PCT/US1996/009623 patent/WO1996040750A1/en active IP Right Grant
- 1996-06-07 DK DK96919241T patent/DK0885242T3/da active
- 1996-06-07 EP EP96919241A patent/EP0885242B1/en not_active Expired - Lifetime
- 1996-06-07 JP JP9501903A patent/JP3059218B2/ja not_active Expired - Lifetime
- 1996-06-07 IL IL12210296A patent/IL122102A/en not_active IP Right Cessation
- 1996-06-07 PT PT96919241T patent/PT885242E/pt unknown
- 1996-06-07 ES ES96919241T patent/ES2303338T3/es not_active Expired - Lifetime
- 1996-06-07 AR ARP960103057A patent/AR003431A1/es active IP Right Grant
- 1996-08-02 TW TW085109336A patent/TW518341B/zh not_active IP Right Cessation
-
1997
- 1997-12-01 MX MX9709315A patent/MX9709315A/es unknown
- 1997-12-05 NO NO19975705A patent/NO317737B1/no not_active IP Right Cessation
-
1999
- 1999-01-22 HK HK99100309A patent/HK1015380A1/xx not_active IP Right Cessation
-
2000
- 2000-04-13 US US09/549,090 patent/US6465430B1/en not_active Expired - Lifetime
-
2004
- 2004-03-29 NO NO20041296A patent/NO331550B1/no not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011057690A (ja) * | 2002-09-18 | 2011-03-24 | Ortho-Mcneil Pharmaceutical Inc | 血小板および造血幹細胞の産生の増大方法 |
JP2007504132A (ja) * | 2003-08-28 | 2007-03-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 受容体に結合するペプチドおよび化合物 |
JP2008532505A (ja) * | 2005-03-10 | 2008-08-21 | ナスカセル テクノロジーズ アーゲー. | 二量体または多量体のマイクロタンパク質 |
JP2017536330A (ja) * | 2014-09-11 | 2017-12-07 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤 |
JP2020528903A (ja) * | 2017-07-26 | 2020-10-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 標的放射線治療誘発性血管完全性を保護する方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3059218B2 (ja) | トロンボポエチン受容体に結合するペプチドおよび化合物 | |
US5932546A (en) | Peptides and compounds that bind to the thrombopoietin receptor | |
US6506362B1 (en) | Labeled compounds that bind to a thrombopoietin receptor | |
US8227422B2 (en) | Peptides and compounds that bind to a receptor | |
US5869451A (en) | Peptides and compounds that bind to a receptor | |
WO1996040189A1 (en) | Peptides and compounds that bind to a receptor | |
CZ134099A3 (cs) | Inhibitory serinových proteáz, zejména proteázy viru hepatitidy C NS3 | |
KR19990022656A (ko) | 에리트로포이에틴 수용체(epo-r)에 결합하는 화합물 및 펩티드 | |
JP4848277B2 (ja) | 受容体に結合するペプチドおよび化合物 | |
AU704215C (en) | Peptides and compounds that bind to a thrombopoietin receptor | |
WO1998057991A1 (en) | Peptides and compounds that bind to the il-5 receptor | |
AU3449797A (en) | Peptides and compounds that bind to the il-5 receptor | |
NZ501633A (en) | Peptides and compounds that bind to the IL-5 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090421 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090421 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100421 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110421 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110421 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120421 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120421 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130421 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130421 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140421 Year of fee payment: 14 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |